Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III lot-consistency study of GSK HPV-16/18 AS04-adjuvanted vaccine in healthy women aged 18-25 years
2005-001667-58Phase 3Completed
- Sponsor
- GSK
- Start
- Sep 2005
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of recombinant human papillomavirus bivalent (types 16 and 18) vaccine in human papillomavirus infection and cervical dysplasia (CIN) (4 arms), sponsored by GSK. Primary endpoints: Anti-HPV-16/18 seroconversion and seropositivity rates at Month 7, Immunogenicity consistency across three industrial-scale lots and 1 more. Started Sep 2005; status: completed.
02
Drugs
recombinant human papillomavirus bivalent (types 16 and 18) vaccine
03
Conditions
human papillomavirus infectioncervical dysplasia (CIN)
Beyond the preview
Go deeper on 2005-001667-58.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001667-58.